NCT05666687 is a Phase 1 clinical trial of MIJ821 in Major Depressive Disorder, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT05666687?

NCT05666687 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT05666687?

Interventions in NCT05666687: MIJ821.

What condition does NCT05666687 study?

NCT05666687 studies Major Depressive Disorder.

Is NCT05666687 still recruiting?

NCT05666687 is currently completed. Last updated 1 April 2024.

Last reviewed 2024-04-01 · How we verify

NCT05666687

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain

Completed Phase 1 Last updated 1 April 2024

What this trial tests

Phase 1 trial testing MIJ821 in Major Depressive Disorder in 10 participants. Completed in 7 November 2023.

Timeline

11 January 2023

Primary endpoint
7 November 2023

7 November 2023

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	basic science
Enrollment	10
Start date	11 January 2023
Primary completion	7 November 2023
Estimated completion	7 November 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

MIJ821 — full drug profile →

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 45, male only, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to confirm binding of MIJ821 to the NR2B-containing NMDA receptors in the human brain and assess the PC-RO relationship over time using positron emission tomography (PET).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Glutamatergic Modulators for Major Depression from Theory to Clinical Use.
McIntyre RS, Jain R. · · 2024 · cited 31× · PMID 39150594 · DOI 10.1007/s40263-024-01114-y

Verify or expand the search:

Other trials of MIJ821

Trials testing the same drug.

NCT03756129 — Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression · Phase 2 · completed

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05666687 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 1 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05666687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing